Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study
Journal of Nephrology · 2026
DOI: 10.1093/joneph/aajag094 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Nephrology, 2026. Verfasst von Yanli Fang und 9 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical College, Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Naphthyridines, Sodium-Glucose Transporter 2 Inhibitors, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit nennt 17 Literaturangaben. Gefördert von: Zhejiang Provincial Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
This study aimed to evaluate the efficacy and safety of finerenone, with or without combination therapy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) or renin-angiotensin system inhibitors (RASi), in Chinese patients with non-diabetic chronic kidney disease (non-diabetic CKD) at different follow-up time points.
Methods
Patients with non-diabetic CKD who received finerenone treatment from March 2023 to August 2025 were retrospectively enrolled. According to the treatment regimens, patients were divided into four groups: finerenone monotherapy group (without SGLT2i or RASi), finerenone + SGLT2i group, finerenone + RASi group, and finerenone + SGLT2i + RASi group. The main evaluated indicators included urine albumin-to-creatinine ratio (UACR), urine protein-to-creatinine ratio (UPCR), serum creatinine (Scr), estimated glomerular filtration rate (eGFR), and serum potassium (K+) levels.
Results
A total of 483 patients were enrolled in this study, including 229 males (47.41%); baseline UACR was 520.1 (interquartile range [IQR], 259.2–993.9) mg/g. After receiving finerenone treatment for 18 months, the UACR decreased by 69.18%. During the study period, the change in eGFR remained stable, with only 2.48% of patients experiencing an eGFR decline >30%. Hyperkalemia occurred in only 6 patients (1.24%), indicating a good safety profile during the medication period.
Conclusion
Finerenone can effectively reduce proteinuria in patients with non-diabetic CKD. Dual or triple combination therapy demonstrated more pronounced effects, with an overall favorable safety profile. Nevertheless, careful monitoring of short-term changes in eGFR and serum K+ levels remains essential during finerenone therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Clinical College, Wenzhou Medical University, Wenzhou, China.
- Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
ORCID-Profile: Yanli Fang, Huidi Zhang
Förderung
- Zhejiang Provincial Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Fang, Y., Shao, Y., Lin, X., Xu, Q., Shang, Y., Chen, M., Chen, S., Lv, Y., Zhang, J., & Zhang, H. (2026). Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study. Journal of Nephrology. https://doi.org/10.1093/joneph/aajag094
Vancouver
Fang Y, Shao Y, Lin X, Xu Q, Shang Y, Chen M, et al. Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study. Journal of Nephrology. 2026. doi:10.1093/joneph/aajag094
BibTeX
@article{Fang2026,
author = {Fang, Yanli and Shao, Yun and Lin, Xinyi and Xu, Qihui and Shang, Yu and Chen, Mingli and Chen, Siyi and Lv, Yinqiu and Zhang, Jianna and Zhang, Huidi},
title = {Efficacy and safety of finerenone with or without combination therapy in patients with non-diabetic chronic kidney disease: a real-world observational study},
journal = {Journal of Nephrology},
year = {2026},
doi = {10.1093/joneph/aajag094}
}
EUVIMED